Charles Wallace's questions to Evaxion Biotech A/S (EVAX) leadership • Q2 2025
Question
Charles Wallace from H.C. Wainwright asked about the upcoming two-year EVX-01 data presentation at ESMO, seeking details on how the clinical outcomes will compare to the one-year data and the number of patients involved in both the two-year data set and the three-year extension.
Answer
Birgitte Runa, Interim CEO and CSO, stated that the two-year data for EVX-01 has not yet been disclosed but confirmed that 11 patients remain active in the trial. She explained that the extension phase will involve a subset of these patients receiving EVX-01 as a monotherapy to better understand its standalone effect, with more details on patient numbers to be provided later.